LSL Web-Exclusive Content

  1. FDA Leads, C-Suite Lags Continuous Manufacturing Acceptance
    6/13/2019

    What happened to the continuous manufacturing (CM) revolution that was barreling down the biopharma turnpike? One measurement of progress is the five FDA-approved drugs utilizing CM. I’ve heard positive dispositions on how the FDA is doing all it can to break down the adoption doors. But there’s a sentiment within the industry CM gets stuck in the C-Suite.  

  2. Are Biopharma's Strong Pipeline Innovations Reaching Patients?
    6/13/2019

    The number of new chemical entities gaining FDA approval more than doubled from 2017 to 2018. Global R&D spending increased 3.5%. The pipeline is strong, but how many innovations are actually reaching patients?

  3. An Analysis Of 2018 FDA Warning Letters Citing Data Integrity Failures
    6/12/2019

    FDA enforcement for failures in data integrity and data governance began almost 20 years ago, and these areas remain as enforcement initiatives of the FDA and other global health authorities to this day.

  4. How Important Is Geography To Today’s Outsourcing?
    6/10/2019

    A recent CDMO press release essentially asserted superiority via proximity: Geography as God of outsourcing. I contacted two biopharma executives familiar with the Boston/Cambridge scene for reactions: Michael Kaufman, Senior Vice President, CMC, Mersana Therapeutics, and 15-year veteran of Merck; and George Avgerinos, Senior Vice President of Biologics Operations, Fortress Biotechnologies, and 22-year veteran of BASF/Abbott/Abbvie.

  5. Can The FTC Clear A Path For Biosimilar Access Through The Patent Thicket?
    6/4/2019

    The existence of what we now call “patent thickets” is a threat to the biosimilar industry (as well as to the introduction of affordable generic drugs). The possibility that innovator medications like AbbVie’s Humira (adalimumab) and Amgen’s Enbrel (etanercept) can retain market exclusivity decades beyond their original date of introduction angers all except the manufacturers’ shareholders.

  6. Virtual Patient Registries: Real-World Evidence For Cell And Gene Therapies
    5/31/2019

    In recent years, cell and gene therapies have been generating highly promising results in clinical studies, advancing them toward the market. However, the small number of products launched to date have not been proven commercial successes, with a number of advanced therapies being withdrawn from the EU market and limited sales of CAR-T therapies in the U.S.

  7. Is Continuous Manufacturing Right For Your Drug?
    5/30/2019

    Adapting any manufacturing process to continuous manufacturing requires in-depth chemical and mechanical engineering understanding as well as the right technologies.

  8. Will Biosimilars Solve The Insulin Cost-Conundrum In The U.S.?
    5/28/2019

    The debate on drug pricing is raising questions about why U.S. patients pay some of the highest fees in the world to access prescription medicines. Politicians are putting manufacturers of insulins under particular scrutiny.

  9. “Work Harder” — And Other Ways To Completely Miss The Mark On Quality
    5/24/2019

    Why does “Quality” seem like such a slippery, elusive term? The answer is easy: It’s because the people who claim to know it really don’t. And everyone seems to go along with the rhetoric.

  10. Talking The Talk: How AI-Informed Virtual Assistants Are Changing Clinical Development
    5/23/2019

    The pharmaceutical industry as we know it today has roots that reach back to the apothecaries and pharmacies of the Middle Ages, when drug discovery largely involved sourcing plants and herbs for natural remedies and drug development and testing was an unstructured concept that relied on the hit-or-miss reactions patients experienced.1 Failure was arguably more common than success and, unfortunately for the patients, treatment courses often did not yield optimal results.